Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs)
$68.17
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | GILD Avg Daily Volume: 15,558,300
Last Update: 04/15/14 - 3:59 PM EDT
Volume: 0
YTD Performance: -9.23%
Open: $0.00
Previous Close: $68.17
52 Week Range: $46.70 - $84.88
Oustanding Shares: 1,538,252,914
Market Cap: 102,713,229,521
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 16 17 16 16
Moderate Buy 2 2 2 2
Hold 1 1 1 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.21 1.20 1.21 1.30
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 42.97
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
42.97 36.80 28.47
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-9.38% 34.51% 226.95%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.50 0.41 0.12
Net Income 18.80 0.06 0.02
EPS 121.60 0.18 0.06
Earnings for GILD:
EBITDA 4.87B
Revenue 11.20B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $0.75 $0.95 $3.92 $6.97
Number of Analysts 3 3 3 2
High Estimate $0.92 $1.33 $5.19 $8.83
Low Estimate $0.64 $0.71 $2.95 $5.12
Prior Year $0.45 $0.48 $1.92 $3.92
Growth Rate (Year over Year) 67.41% 98.61% 103.99% 78.09%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Apr 11, 2014 | 11:41 AM EDT

Let's categorize things in this vicious rotation.

By

Dan Fitzpatrick

 | Apr 11, 2014 | 7:30 AM EDT

Do you think I'm looking at yesterday's bloodbath as a buying opportunity?

By

Dan Fitzpatrick

 | Apr 9, 2014 | 8:00 AM EDT

These stocks are broken -- and you can't un-break them

By

Jill Malandrino

 | Apr 7, 2014 | 3:29 PM EDT

TD Ameritrade's Chief Strategist JJ Kinahan explains technology and healthcare sectors were a popular buy, while consumer stocks were net sold, with Apple leading the way.

By

Jim Cramer

 | Apr 1, 2014 | 2:13 PM EDT

Money managers need to be fashionable, and your advantage is that you don't.

By

Bret Jensen

 | Apr 1, 2014 | 11:30 AM EDT

How well an investor masters this technique will determine performance this year.

By

Jim Cramer

 | Apr 1, 2014 | 11:26 AM EDT

These fanciful folks, it seems, just want to make themselves feel better about missing last year's 'phony' rally.

By

Jim Cramer

 | Mar 31, 2014 | 4:22 PM EDT

These shifts are just a function of institutional money management.

By

Jim Cramer

 | Mar 31, 2014 | 6:45 AM EDT

Aerospace, software-as-a-service and biotech are all giving up the ghost.

By

Jim Cramer

 | Mar 29, 2014 | 8:00 AM EDT

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.

After the close Yahoo reported another pathetic quarter. Revenue rose 1.2% to $1.09 billio...
Wow, have not seen an intraday rally like today's to the upside like this for quite some t...
Today's probing low followed by a recovery signals to us that the seasonal pattern of Apri...
Traders couldn't ask for much bigger swings than we've been seeing over the past two sessi...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.